#AACR18: Roche spotlights promising subgroup responses for lung cancer combo with Tecentriq
Merck and Bristol-Myers Squibb aren’t the only big players looking to make a splash in frontline lung cancer. Roche is also looking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
